Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Treatment of hepatitis C].
Schrumpf E, Bjøro K, Bell H, Harthug S, Hellum KB, Myrvang B, Maeland A, Ritland S. Schrumpf E, et al. Among authors: maeland a. Tidsskr Nor Laegeforen. 1996 Jun 10;116(15):1792-4. Tidsskr Nor Laegeforen. 1996. PMID: 8693463 Review. Norwegian.
Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Gutigard BG, Skjaerven R, Prescott LE, Simmonds P. Bell H, et al. Among authors: maeland a. Scand J Infect Dis. 1997;29(1):17-22. doi: 10.3109/00365549709008658. Scand J Infect Dis. 1997. PMID: 9112292 Clinical Trial.
Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study.
Nordøy I, Krarup HB, Bell H, Christensen PB, Elgjo K, von der Lippe B, De Muckadell OS, Maeland A, Ring-Larsen H, Samdal HH, Simmonds P, Skaug K, Tage-Jensen U, Schrumpf E. Nordøy I, et al. Among authors: maeland a. Scand J Gastroenterol. 1997 Dec;32(12):1256-60. doi: 10.3109/00365529709028156. Scand J Gastroenterol. 1997. PMID: 9438325 Clinical Trial.
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, von der Lippe B, Bjøro K, Skaug K, Gutigard BG, Raknerud N, Simmonds P. Bell H, et al. Among authors: maeland a. Scand J Gastroenterol. 1999 Feb;34(2):194-8. doi: 10.1080/00365529950173087. Scand J Gastroenterol. 1999. PMID: 10192200 Clinical Trial.
Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices.
Bjøro K, Krarup H, Bell H, Christophersen P, Evensen S, Frøland SS, Laursen A, B vd Lippe B, Maeland A, Ranek L, et al. Bjøro K, et al. Among authors: maeland a. Scand J Gastroenterol. 1995 Nov;30(11):1119-24. doi: 10.3109/00365529509101617. Scand J Gastroenterol. 1995. PMID: 8578174 Clinical Trial.
111 results